Company intelligence / Profile preview

SeegPharm

Ownership: Private
Development stage: Commercial

Overview

SeegPharm specializes in the co-development and out-licensing of complex generic pharmaceuticals. The company has partnered with Cosette Pharmaceuticals to launch Dapsone 5% Gel for acne in the US market. No clinical trial results are directly reported; as a generic developer, their products are typically approved via bioequivalence rather than new clinical efficacy trials.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

dapsone

Commercial

Indications: Acne

Partnerships

Cosette Pharmaceuticals

Beyond the preview

Go deeper on SeegPharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SeegPharm.